ELV Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -4.28%, SMA50 -7.82%, SMA200 -4.9%). The stock’s 14-day RSI is 38.45 (weak momentum), while the ATR of 11.63 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -29.58% below its high and over 18.03% above its low. Average 10-day trading volume of 826.07 thousand shares is below the 3-month average of 1.43 million, indicating normal recent market interest.

Elevance Health Inc. has 216.87 million shares outstanding. The public float is 216.41 million shares, elevated short interest at 3.11% of float. This equals 6.03 million shares. The short ratio is 3.47 days. Institutional investors hold 93.87% of the float. Insiders own 0.19%. BOUDREAUX GAIL holds 169.93 thousand shares, Gallina John E has 54.32 thousand shares and MCCARTHY GLORIA M has 51.44 thousand shares. Over the past six months, insider transactions show net selling. They sold 5.27 thousand shares across 5 transactions.

Elevance Health Inc. (NYSE:ELV) closed at $400.54 USD, gaining $4.26 (1.07%) from the previous close of $396.28. The stock is currently mid-range between its 52-week high and low $274.84 and $436.24. With a market capitalization of about $86.86 billion, Elevance Health Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.69). Key stats such as the average daily volume over the past year has been around 1.50 million shares, volume is running light vs its 52-week average. Headquartered in Indianapolis, IN, Elevance Health Inc. operates in the Healthcare sector and the Medical - Healthcare Plans industry. Led by CEO Gail Koziara Boudreaux, the company employs approximately 96,615 people and listed since October 30, 2001. Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path.

Elevance Health Inc. last paid a dividend of 6.86 per share, this equals a trailing yield of roughly 1.15%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $891.08. This means the shares are trading below this model’s fair value.

Elevance Health Inc. generated EPS of $25.11 over the past year. Five-year average earnings growth is 6.99%. Wall Street analysts project EPS growth of 5.12% annually over the next five years. The latest quarter delivered EPS of $7.45. The next quarter is forecast at $10.58. Next year's EPS is expected at $12.19. Analyst sentiment is bullish. Analyst rating data shows there are 26 Strong Buy ratings, 18 Buy ratings, 13 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $498.00 to $331.00. The high target offers 24.33% upside. The low target suggests -17.36% downside. The mean target is $413.65. This offers 3.27% upside. Elevance Health Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended July 15, 2026, missed forecasts by 19.97%. The prior quarter beat by 14.05%. Over the last six quarters, Apple has recorded several small beats. These include 4.91% in April 22, 2025.

Elevance Health Inc. trades at a P/E ratio of 17.89, slightly below the S&P 500 average, with a price-to-sales ratio of 0.43 and a price-to-book ratio of 1.95 suggesting the stock is closer to book value. The P/FCF stands at 13.88, also above market averages.

Our AI price prediction model suggests that Elevance Health Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.6%, with price expected at $406.93 by September 03, 2026, within a range of $394.42 to $419.44 3-Month Outlook: Projected rise of 31.58%, reaching $527.03 by November 18, 2026, with a range of $514.20 to $547.12. 1-Year Outlook: Projected loss of -14.92%, with price at $340.78 by August 20, 2027, within a range of $321.44 to $361.41.

Elevance Health Inc. (NYSE:ELV) shares are flat 4.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Elevance Health Inc. trading at a premium to the broader market with a P/E of 17.89. Analyst sentiment is cautious, with the majority of ratings in Market Perform territory and a mean price target of $461.13, suggesting 15.13% upside. Our AI forecast model points to short-term strength (1.6% over two weeks), a medium-term rise (31.58% over three months), and a longer-term loss (-14.92% over one year), with expected trading ranges indicating moderate volatility.